Key facts
- It has raised $62.9M across 13 recorded rounds; the latest was Seed Round ($2.3M) in Mar 2026.
- Notable investors include US National Science Foundation, Founders Capital Partners, National Institute of Standards and Technology, Rose Ventures.
- Affinity Biosensors has filed 26 Form Ds with the SEC since 2010, most recently Dec 2024 ($14.4M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 13 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Affinity Biosensors
Funding rounds
13 roundsAbout Affinity Biosensors
Developer of an antimicrobial susceptibility testing device designed for rapid measurement and observation of bacterial growth and response. The company's device utilizes microfluidic mass sensing and population profiling to analyze individual microbes, providing real-time minimum inhibitory concentration data, enabling healthcare professionals to optimize antibiotic selection, improve patient outcomes, and support antimicrobial stewardship by reducing reliance on empirical treatments and minimizing resistance development.
- Sector
- Healthcare
- HQ
- Santa Barbara, CA, United States
- Founded
- 2006
- Employees
- 29
- Website
- affinitybio.com/
- Ownership
- Privately Held (backing)
Affinity Biosensors doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Affinity Biosensors shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Affinity Biosensors in its N-PORT filings yet. We sweep new filings monthly.